MEDANTA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | MEDANTA | Market Cap | 31,469 Cr. | Current Price | 1,170 ₹ | High / Low | 1,456 ₹ |
| Stock P/E | 62.8 | Book Value | 141 ₹ | Dividend Yield | 0.04 % | ROCE | 19.6 % |
| ROE | 15.2 % | Face Value | 2.00 ₹ | DMA 50 | 1,097 ₹ | DMA 200 | 1,162 ₹ |
| Chg in FII Hold | -0.39 % | Chg in DII Hold | 0.77 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 128 Cr. |
| RSI | 64.2 | MACD | 26.2 | Volume | 3,32,979 | Avg Vol 1Wk | 3,92,503 |
| Low price | 955 ₹ | High price | 1,456 ₹ | PEG Ratio | 1.99 | Debt to equity | 0.07 |
| 52w Index | 42.8 % | Qtr Profit Var | -18.4 % | EPS | 17.3 ₹ | Industry PE | 48.0 |
📊 Medanta shows moderate fundamentals with ROCE at 19.6% and ROE at 15.2%, which are decent but not outstanding. The company is nearly debt-free (0.07 debt-to-equity), ensuring financial stability. Dividend yield is very low at 0.04%, limiting income potential. The P/E of 62.8 is significantly higher than the industry average of 48.0, indicating overvaluation. PEG ratio of 1.99 also suggests the stock is expensive relative to growth. Current price ₹1,170 is above the 50 DMA (₹1,097) and near the 200 DMA (₹1,162), showing consolidation. RSI at 64.2 and MACD positive (26.2) indicate bullish momentum, but quarterly PAT declined from ₹128 Cr. to ₹107 Cr. (-18.4%), raising concerns.
💡 Ideal Entry Zone: ₹1,050 – ₹1,120 (near 200 DMA support).
📈 Exit Strategy: Investors already holding should consider a medium-term horizon (2–3 years). Partial profit booking can be done near ₹1,400–₹1,450 resistance levels. Long-term holding should be cautious given high valuations and weak dividend yield, despite decent ROE and ROCE.
Positive
- ROCE (19.6%) and ROE (15.2%) show moderate efficiency.
- Debt-to-equity ratio of 0.07 ensures financial stability.
- DII holdings increased (+0.77%), showing domestic institutional support.
- Stock trading above DMA levels with bullish momentum indicators.
Limitation
- High P/E (62.8) compared to industry average (48.0).
- PEG ratio of 1.99 indicates overvaluation relative to growth.
- Dividend yield of only 0.04% offers negligible income.
- Quarterly PAT declined (-18.4%), raising earnings concerns.
Company Negative News
- Recent quarterly profit decline from ₹128 Cr. to ₹107 Cr.
Company Positive News
- DII stake increased (+0.77%), reflecting domestic confidence.
- Strong brand presence in healthcare services.
Industry
- Healthcare sector remains resilient with long-term demand drivers.
- Industry P/E of 48.0 reflects optimism in hospital and healthcare stocks.
Conclusion
⚠️ Medanta is financially stable with moderate profitability, but valuations are stretched and dividend yield is negligible. Ideal entry is near ₹1,050–₹1,120. Existing investors should hold cautiously for 2–3 years, with partial profit booking near ₹1,400–₹1,450 resistance levels.